ID: ALA2407759

Max Phase: Preclinical

Molecular Formula: C23H21N7O2S

Molecular Weight: 459.54

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(=O)N1CCC(n2cc(-c3cnc(N)c4oc(-c5cccc6nnsc56)cc34)cn2)CC1

Standard InChI:  InChI=1S/C23H21N7O2S/c1-13(31)29-7-5-15(6-8-29)30-12-14(10-26-30)18-11-25-23(24)21-17(18)9-20(32-21)16-3-2-4-19-22(16)33-28-27-19/h2-4,9-12,15H,5-8H2,1H3,(H2,24,25)

Standard InChI Key:  XDCWLOMVUOZXFY-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 459.54

Molecular Weight (Monoisotopic): 459.1477

AlogP: 4.13

#Rotatable Bonds: 3

Polar Surface Area: 115.96

Molecular Species: NEUTRAL

HBA: 9

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 5.45

CX LogP: 1.65

CX LogD: 1.64

Aromatic Rings: 5

Heavy Atoms: 33

QED Weighted: 0.43

Np Likeness Score: -0.95

References

1. Hornberger KR, Berger DM, Crew AP, Dong H, Kleinberg A, Li AH, Medeiros MR, Mulvihill MJ, Siu K, Tarrant J, Wang J, Weng F, Wilde VL, Albertella M, Bittner M, Cooke A, Gray MJ, Maresca P, May E, Meyn P, Peick W, Romashko D, Tanowitz M, Tokar B..  (2013)  Discovery and optimization of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1.,  23  (16): [PMID:23850198] [10.1016/j.bmcl.2013.06.053]

Source

Source(1):

• Scientific Literature